<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7450</journal-id>
<journal-title><![CDATA[Revista Colombiana de Psiquiatría]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.psiquiatr.]]></abbrev-journal-title>
<issn>0034-7450</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Psiquiatria.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74502024000400426</article-id>
<article-id pub-id-type="doi">10.1016/j.rcp.2022.06.001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility]]></article-title>
<article-title xml:lang="es"><![CDATA[Efectividad Del Palmitato de Paliperidona en la Adherencia al Tratamiento y Las Recaídas en la Población Adulta Con Esquizofrenia: Un estudio en Imagen Especular de un Año en un Centro de salud Mental en Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribero]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castilloux]]></surname>
<given-names><![CDATA[Anne-Marie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Agudelo]]></surname>
<given-names><![CDATA[Lina Maria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machnicki]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[Vanesa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perocco]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillon]]></surname>
<given-names><![CDATA[Genaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moride]]></surname>
<given-names><![CDATA[Yola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,E.S.E. Hospital Mental de Antioquia  ]]></institution>
<addr-line><![CDATA[Bello Antioquia]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,YolaRX Consultants  ]]></institution>
<addr-line><![CDATA[Montreal Quebec]]></addr-line>
<country>Canada</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Janssen-Cilag Farmacéutica Ltda  ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Janssen-Cilag S.A.  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Janssen-Cilag Farmacêutica Ltda  ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,The State University of New Jersey  ]]></institution>
<addr-line><![CDATA[New Jersey ]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>53</volume>
<numero>4</numero>
<fpage>426</fpage>
<lpage>434</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74502024000400426&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74502024000400426&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74502024000400426&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The benefits of long-acting injectable antipsychotics have been documented in several observational studies, but data remain scarce in Latin America. This study aimed at evaluating the effectiveness of paliperidone palmitate once monthly (PP1M) on treatment adherence and relapse in the schizophrenia population followed in a government-funded mental health care facility in Colombia.  Methods:  A mirror-image study was conducted. Adult schizophrenia patients treated with oral antipsychotics who subsequently received &#8805;2 PP1M injections between Jan. 1st, 2015 and Oct. 31st, 2018 were included. The study consisted of two retrospective phases: 12 months before and after the first PP1M injection. Outcomes were treatment adherence (proportion of days covered &#8805;80%), hospitalized relapse, hospital length of stay, and non-hospitalised relapse. Effect of PP1M on outcomes was assessed through multivariable conditional Poisson regression.  Results:  123 patients were eligible (mean age, 30.3 years; 79.7% males). Adherence was 23.6% in the pre-phase and 89.4% in the post-phase (RR = 3.77; 95%CI, 2.75-5.17). The proportion of patients with hospitalised relapse decreased from 46.3% to 35.0% (RR = 0.76; 95%CI, 0.590.99). In the 75 (61.0%) patients who continued PP1M throughout post-phase, beneficial effect on hospitalised relapse was stronger (RR = 0.64; 95%CI, 0.42-0.98). The proportion of patients with non-hospitalised relapse symptoms increased from 6.5% to 18.7% (RR = 2.27; 95%CI, 1.11-4.64).  Conclusions:  PP1M initiation led to a dramatic improvement in treatment adherence and a decrease in hospitalised relapse. Observed increase in non-hospitalised relapse may be explained by a decrease in severity. Limitations are absence of a parallel comparison group and a generalisability limited to the population treated at this facility. Study provides data for the Latin America region and strength is the assessment of non-hospitalised relapse symptoms.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Los beneficios de los antipsicóticos inyectables de acción prolongada se han documentado en varios estudios observacionales, pero los datos de América Latina siguen siendo escasos. El estudio se dirige a evaluar la efectividad del palmitato de paliperidona 1 vez al mes (PP1M) en la adherencia al tratamiento y las recaídas en la población con esquizofrenia seguida en un centro público de salud mental en Colombia.  Métodos:  Se realizó un estudio en imagen especular. Se incluyó a pacientes adultos con esquizofrenia tratados con antipsicóticos orales que posteriormente recibieron &gt; 2 PP1M entre el 1 de enero de 2015 y el 31 de octubre de 2018. El estudio consistió en 2 fases retrospectivas: 12 meses antes y después de la primera inyección de PP1M. Se evaluó la adherencia al tratamiento (proporción de días cubiertos &#8805; 80%), la recaída hospitalizada, la duración de la estancia hospitalaria y la recaída no hospitalizada. El efecto del PP1M se evaluó mediante la regresión de Poisson.  Resultados:  Fueron elegibles 123 pacientes (media de edad, 30,3 años; el 79,7% varones). La adherencia fue del 23,6% en la fase previa y del 89,4% en la segunda (RR = 3,77; IC95%, 2,75-5,17). La proporción de pacientes con recaída hospitalizada disminuyó del 46,3 al 35,0% (RR = 0,76; IC95%, 0,59-0,99). De los 75 pacientes (61,0%) que continuaron PP1M en la segunda fase, el efecto beneficioso en la recaída hospitalizada fue más fuerte (RR = 0,64; IC95%, 0,42- 0,98). La proporción de pacientes con síntomas de recaída no hospitalizados aumentó del 6,5 al 18,7% (RR = 2,27; IC95%, 1,11-4,64).  Conclusiones:  La iniciación de PP1M llevó a una drástica mejora en la adherencia al tratamiento y a una disminución de la recaída hospitalizada. El aumento observado en la recaída no hospitalizada puede explicarse por una disminución de la gravedad. Las limitaciones son la ausencia de un grupo de comparación paralelo y que la generalizabilidad se limita a la población tratada en este centro. La fortaleza del estudio es la presentación de datos de la región de América Latina y la evaluación de síntomas de recaída no hospitalizada.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Antipsychotics]]></kwd>
<kwd lng="en"><![CDATA[Paliperidone palmitate]]></kwd>
<kwd lng="en"><![CDATA[Schizophrenia]]></kwd>
<kwd lng="en"><![CDATA[Adherence]]></kwd>
<kwd lng="en"><![CDATA[Relapse]]></kwd>
<kwd lng="es"><![CDATA[Antipsicóticos]]></kwd>
<kwd lng="es"><![CDATA[Palmitato de paliperidona]]></kwd>
<kwd lng="es"><![CDATA[Esquizofrenia]]></kwd>
<kwd lng="es"><![CDATA[Adherencia]]></kwd>
<kwd lng="es"><![CDATA[Recaída]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Colombia la prevalencia de la esquizofrenia representa el 1% de la población]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chong]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Teoh]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[DB-C]]></given-names>
</name>
<name>
<surname><![CDATA[Kotirum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chiou]]></surname>
<given-names><![CDATA[C-F]]></given-names>
</name>
<name>
<surname><![CDATA[Chaiyakunapruk]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global economic burden of schizophrenia: a systematic review]]></article-title>
<source><![CDATA[Neuropsychiatr Dis Treat]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>357-73</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[DE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Term Treatment Goals: Enhancing Healthy Outcomes]]></article-title>
<source><![CDATA[CNS Spectr]]></source>
<year>2003</year>
<volume>8</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>26-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hartry]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Touya]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Broder]]></surname>
<given-names><![CDATA[MS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2018</year>
<volume>21</volume>
<page-range>127-34</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emsley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chiliza]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Asmal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[BH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The nature of relapse in schizophrenia]]></article-title>
<source><![CDATA[BMC Psychiatry]]></source>
<year>2013</year>
<volume>13</volume>
<page-range>50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alphs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nasrallah]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Bossie]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy]]></article-title>
<source><![CDATA[Int Clin Psychopharmacol]]></source>
<year>2016</year>
<volume>31</volume>
<page-range>202-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leucht]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Heres]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kissling]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Leucht]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oral versus Depot Antipsychotic Drugs for Schizophrenia: A Critical Systematic Review and Meta-Analysis of Randomised Long-Term Trials]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Lonndon ]]></publisher-loc>
<publisher-name><![CDATA[Centre for Reviews and Dissemination (UK)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kishimoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nitta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borenstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Correll]]></surname>
<given-names><![CDATA[CU.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2013</year>
<volume>74</volume>
<page-range>957-65</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Sistema de Trámites en Línea-Consultas Públicas</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Johnson &amp; Johnson</collab>
<source><![CDATA[Landmark schizophrenia data that brings hope in breaking the cycle of hospitalization and incarcelation receives FDA approval for inclusion in INVEGA SUSTENNA® (paliperidone palmitate) label]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcus]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Zummo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pettit]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Doshi]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge]]></article-title>
<source><![CDATA[J Manag Care Spec Pharm]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>754-68</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Demers]]></surname>
<given-names><![CDATA[M-F]]></given-names>
</name>
<name>
<surname><![CDATA[Doyon-Kemp]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Duchesneau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Halme]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Masson]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada]]></article-title>
<source><![CDATA[Schizophr Res]]></source>
<year>2017</year>
<volume>185</volume>
<page-range>96-100</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Moreno]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[DG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EPA-0322-Adherence and Reduction of Admissions in Patients Treated with Paliperidone Palmitate]]></article-title>
<source><![CDATA[Eur Psychiatry]]></source>
<year>2014</year>
<numero>^s29</numero>
<issue>^s29</issue>
<supplement>29</supplement>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lefebvre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Muser]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2017</year>
<volume>39</volume>
<page-range>1380-95</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<source><![CDATA[Transparencia y Acceso a la Información Pública, Hospital Mental de Antioquia]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nau]]></surname>
<given-names><![CDATA[DP.]]></given-names>
</name>
</person-group>
<source><![CDATA[Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence]]></source>
<year></year>
<page-range>3</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weiden]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kozma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grogg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Locklear]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia]]></article-title>
<source><![CDATA[Psychiatr Serv Wash DC]]></source>
<year>2004</year>
<volume>55</volume>
<page-range>886-91</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DerSarkissian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lefebvre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2018</year>
<volume>40</volume>
<page-range>1496-508</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emond]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[El Khoury]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2019</year>
<volume>35</volume>
<page-range>407-16</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<source><![CDATA[A Study for Schizophrenia Relapse Prediction]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Janssen Research &amp; Development, LLC</collab>
<source><![CDATA[Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled]]></source>
<year></year>
<publisher-name><![CDATA[Parallel-Group Study]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Forest Laboratories</collab>
<source><![CDATA[A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[A]]></surname>
<given-names><![CDATA[randomized]]></given-names>
</name>
</person-group>
<source><![CDATA[double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<source><![CDATA[Risperdal Consta Trial of Relapse Prevention and Effectiveness]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
